OncLive SOSS

Authors

Francois-Clement Bidard, MD, PhD

Latest:

Dr. Bidard on the FDA Approval of Elacestrant in ER+/HER2– Metastatic Breast Cancer

François-Clément Bidard, MD PhD, discusses the significance of the FDA approval of elacestrant in patients with estrogen receptor–positive, HER2-negative metastatic breast cancer and key efficacy and safety data from the phase 3 EMERALD trial.

Francoise G. Pradel, PhD

Latest:

Racial/Ethnic and Age Disparities in Chemotherapy Selection for Colorectal Cancer

Studies have evaluated racial/ethnic and age disparities in whether patients receive chemotherapy for nonmetastatic colo-rectal cancer

Francoise Horand

Latest:

Erythrocytes Used as Tumor Antigen Delivery System

FranÃ§oise Horand, director, R&D Operations, Erytech Pharma, discusses a study investigating the use of erythrocytes as a tumor antigen delivery system to target antigen-presenting cells and induce efficient immune response against tumors.

Frank A. Sinicrope, MD

Latest:

Dr Sinicrope on the Clinical Implications of the ATOMIC Trial for Stage III dMMR CRC

Frank A. Sinicrope, MD, discuses the implications of data with atezolizumab plus adjuvant mFOLFOX6 for the management of stage III, dMMR colon cancer.

Frank A. Vicini, MD

Latest:

Dr. Vicini on the Potential Utility of the DCISionRT Test in HER2+ DCIS of the Breast

Frank A. Vicini, MD, discusses the potential utility of using the DCISionRT test to determine treatment benefit in the phase 3 NRG-NSABP-B43 trial in HER2-positive ductal carcinoma in situ of the breast.

Frank A. Vicini, MD, FACR

Frank delaRama, RN, MS, AOCNS

Latest:

Frank delaRama on Patient Education in Prostate Cancer

Frank delaRama, RN, MS, AOCNS®, from the Palo Alto Medical Foundation, explains the role of oncology nurse navigators in providing relevant information to men with prostate cancer.

Frank E. Mott, MD

Latest:

Dr. Mott on Sequencing of Treatments with NSCLC

Frank E. Mott, MD, associate professor, Department of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the sequencing of treatments for patients with non-small cell lung cancer (NSCLC).

Frank E. Mott, MD, FACP

Latest:

Dr. Mott Discusses Targeted Therapy for ALK+ NSCLC

Frank E. Mott, MD, FACP, department of Thoracic Head and Neck Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses taregeted therapy for ALK-positive non-small cell lung cancer (NSCLC).

Latest:

Argumentum Ad Populum: Medical Wikis 101

What exactly is a medical wiki, and for that matter, a wiki in general? Are these resources useful to you and your patients?

Frank Vicini, MD

Latest:

Hypofractionated and Stereotactic Body Radiotherapy in Prostate Cancer

Despite limited data comparing stereotactic body radiation therapy to standard or hypofractionated radiotherapy with regards to long-term clinical outcomes and toxicity profiles, the data are promising and appropriately selected patients can be offered such an approach off-protocol.

Frankie Ann Holmes, MD

Latest:

Dr. Holmes on Neoadjuvant Endocrine Therapy in Breast Cancer

Frankie Ann Holmes, MD, a physician at Texas Oncology, discusses neoadjuvant endocrine therapy for patients with breast cancer.

Fred C. Kass, MD

Latest:

Dr. Kass on Optimal Treatment Sequencing in HER2-Positive Breast Cancer

Fred C. Kass, MD, oncology/hematology, internal medicine, Cancer Center of Santa Barbara, discusses challenges associated with optimal treatment sequencing for patients with HER2-positive breast cancer.

Latest:

TechSectors: Connectivity: Improving Physician-Patient Communication

More than ever before, healthcare professionals are strapped for time.

Fred Hirsch, MD, PhD, University of Colorado School of Medicine

Fred R. Hirsch, MD, PhD

Latest:

Dr Hirsch on the Benefits of Tissue vs Liquid Biopsy in NSCLC

Fred R. Hirsch, MD, PhD, discusses the pros and cons of completing a tissue biopsy compared with a liquid biopsy in non–small cell lung cancer.

Fred Saad, CQ, MD, FRCS, FCAHS

Fred Saad, CQ, MD, FRCS, FCAHS, is the director of Prostate Cancer Research at Montreal Cancer Institute, Centre Hospitalier de l’Université de Montréal. He is also a full professor in the Department of Surgery at Université de Montréal and a uro-oncologist in the Urology Department at the University of Montreal Health Center.

Latest:

Dr Saad on the Importance of Timing When Incorporating Radium-223 Into Prostate Cancer Treatment

Fred Saad, MD, discusses the importance of timing when incorporating radium-223 into prostate cancer treatment.

Fred Saad, MD, FRCS

Latest:

The ARANOTE Phase 3 Trial of Darolutamide Plus Androgen-Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer: Efficacy and Safety by Disease Volume

Dr. Fred Saad presents a post-hoc analysis of the Phase 3 ARANOTE trial, demonstrating that darolutamide plus androgen-deprivation therapy significantly improves radiographic progression-free survival and delays metastatic castration-resistant prostate cancer in patients with metastatic hormone-sensitive prostate cancer, with consistent efficacy across disease volume subgroups and a favorable safety profile.

Fred Schumacher, PhD, MPH

Latest:

Fred Schumacher on Genetic Risk Factors of Prostate Cancer

Fred Schumacher, PhD, MPH, associate professor, Case Western Reserve University, discusses a study that led to the identification of genetic risk factors of prostate cancer.

Frederic Triebel, MD, PhD

Latest:

Dr. Triebel on the Rationale for a Novel Immunotherapy Combination in Melanoma

Frederic Triebel, MD, PhD, chief scientific officer and chief medical director, Immutep Ltd, discusses the rationale for a novel immunotherapy combination in patients with unresectable or metastatic melanoma.